ES2114615T3 - Nueva sonda para el diagnostico de tumores o la terapia de tumores. - Google Patents

Nueva sonda para el diagnostico de tumores o la terapia de tumores.

Info

Publication number
ES2114615T3
ES2114615T3 ES93917719T ES93917719T ES2114615T3 ES 2114615 T3 ES2114615 T3 ES 2114615T3 ES 93917719 T ES93917719 T ES 93917719T ES 93917719 T ES93917719 T ES 93917719T ES 2114615 T3 ES2114615 T3 ES 2114615T3
Authority
ES
Spain
Prior art keywords
tumor
diagnosis
new probe
therapy
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917719T
Other languages
English (en)
Inventor
Peter Gruss
Catharina Maulbecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Application granted granted Critical
Publication of ES2114615T3 publication Critical patent/ES2114615T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

UN AGENTE TERAPEUTICO O DE DIAGNOSIS DE ACUERDO CON LA INCENCION CONTIENEN COMO SUSTANCIA ACTIVA AL MENOS UN ACIDO NUCLEICO QUE SE HIBRIDIZA CON UN GEN PAX, O AL MENOS UNA PROTEINA PAX, O AL MENOS UN ANTICUERPO CONTRA UNA PROTEINA PAX O UNO DE SUS DERIVADOS. LOS AGENTES DE ACUERDO CON LA INVENCION SE UTILIZAN PARA LA DIAGNOSIS Y/O TRATAMIENTO DE TUMORES, ASI COMO SE UTILIZAN COMO ACIDO NUCLEICO ANTISENSE PARA LA INHIBICION DE EXPRESION DE UN GEN.
ES93917719T 1992-08-03 1993-08-02 Nueva sonda para el diagnostico de tumores o la terapia de tumores. Expired - Lifetime ES2114615T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4225569A DE4225569C2 (de) 1992-08-03 1992-08-03 Verwendung einer Sonde zur Tumordiagnostik oder Tumortherapie

Publications (1)

Publication Number Publication Date
ES2114615T3 true ES2114615T3 (es) 1998-06-01

Family

ID=6464707

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917719T Expired - Lifetime ES2114615T3 (es) 1992-08-03 1993-08-02 Nueva sonda para el diagnostico de tumores o la terapia de tumores.

Country Status (9)

Country Link
US (1) US5747250A (es)
EP (1) EP0655926B1 (es)
JP (1) JPH07509477A (es)
AT (1) ATE162721T1 (es)
CA (1) CA2141678A1 (es)
DE (2) DE4225569C2 (es)
DK (1) DK0655926T3 (es)
ES (1) ES2114615T3 (es)
WO (1) WO1994003196A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028184A (en) * 1996-12-31 2000-02-22 Max-Plank-Gesellschaft Zur Forderung Der Wissenschaften E.V. Pax6 and Pax4 nucleic acid mixtures
DE19605105A1 (de) 1996-02-12 1997-08-14 Gsf Forschungszentrum Umwelt Neue Sonde zur Früherkennung von epithelialen Dysplasien des mehrschichtigen Plattenepithels sowie zur Tumordiagnostik und Tumortherapie von Plattenepithelkarzinomen
EP0958357B1 (en) * 1996-12-31 2005-11-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel method for testing the differentiation status in pancreatic cells of a mammal
EP1288311A3 (en) * 1996-12-31 2004-09-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for testing small pharmaceutically active molecules in the activation of Pax4 and production of insulin producing beta-cells
GB9811598D0 (en) * 1998-05-30 1998-07-29 Imp College Innovations Ltd Diagnosis and treatment of cancer
GB9903841D0 (en) * 1999-02-20 1999-04-14 Imp College Innovations Ltd Diagnosis and treatment of cancer
AU2139001A (en) * 1999-12-22 2001-07-03 Mcgill University Modulation of PAX-2 for controlled apoptosis or survival of cells
WO2001052789A2 (en) 2000-01-20 2001-07-26 The Brigham And Women's Hospital, Inc. PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF
CN1320634A (zh) * 2000-04-27 2001-11-07 上海博德基因开发有限公司 一种新的多肽——人含配对盒结构域的蛋白20和编码这种多肽的多核苷酸
CN1320616A (zh) * 2000-04-27 2001-11-07 上海博德基因开发有限公司 一种新的多肽——人Pax蛋白17和编码这种多肽的多核苷酸
CN1321681A (zh) * 2000-04-29 2001-11-14 上海博德基因开发有限公司 一种新的多肽——人Pax蛋白11.3和编码这种多肽的多核苷酸
US7601696B1 (en) 2003-08-22 2009-10-13 University Of South Florida Oct-1 as an oncoprotein and use of nucleic acid inhibitors of Oct-1 for cancer treatment
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
KR101088885B1 (ko) * 2008-12-23 2011-12-07 연세대학교 산학협력단 바이오프로브, 그 제조방법, 상기를 사용한 분석 장치 및 분석 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009974A1 (en) * 1989-12-27 1991-07-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Diagnostic probe for detecting human stomach cancer
ATE338134T1 (de) * 1991-02-08 2006-09-15 Aventis Pharma Sa Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen

Also Published As

Publication number Publication date
HK1002531A1 (en) 1998-08-28
US5747250A (en) 1998-05-05
EP0655926B1 (de) 1998-01-28
WO1994003196A1 (de) 1994-02-17
ATE162721T1 (de) 1998-02-15
DK0655926T3 (da) 1998-09-21
JPH07509477A (ja) 1995-10-19
DE4225569C2 (de) 1996-04-25
DE4225569A1 (de) 1994-02-10
EP0655926A1 (de) 1995-06-07
CA2141678A1 (en) 1994-02-17
DE59308082D1 (de) 1998-03-05

Similar Documents

Publication Publication Date Title
ES2114615T3 (es) Nueva sonda para el diagnostico de tumores o la terapia de tumores.
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
FI970768L (fi) Kasvainten geeniterapiahoito endoteelisoluspesifisellä, solusyklistä riippuvalla vaikuttavalla aineella
HN1999000184A (es) Combinaciones para la diabetes
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
FI955552A0 (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
DE69737684D1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
ES2181298T3 (es) Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos.
ES2018729A6 (es) Un metodo para preparar una variante de activador de plasmogeno de tejido.
PT695360E (pt) Adenovirus recombinantes deficientes, para a terapia genica de tumores
ES2143641T3 (es) Expresion en superficie de una enzima en la terapia genica a base de promedicamentos.
DE69837754D1 (de) Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
DK2182064T3 (da) Gen udtrykt i prostatakræft
ATE226094T1 (de) Verfahren zur arzneistoffabgabe mittels gentherapie
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
ES2061521T3 (es) Proteinas con actividad glutation-s-transferasa, secuencias de adn, anticuerpos, poxvirus y medicamentos para la prevencion de la equistosomiasis.
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
BR0108609A (pt) Anticorpo com especificidade pelo câncer de cólon
DK131586A (da) Transdermalt, antiallergisk, farmaceutisk praeparat
ES2040765T3 (es) Procedimiento para preparar un agente para el tratamiento de enfermedades angiogenas o tumores.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 655926

Country of ref document: ES